CAR-DC cell therapy for end-stage lung fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a new type of immunotherapy called CAR-DC for people with advanced idiopathic pulmonary fibrosis (IPF) who are not improving on standard treatments and are eligible for a lung transplant but choose not to have one. The goal is to see if this treatment can help slow or stop the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have a diagnosis of IPF.
- Your lung function has been getting worse despite taking standard IPF medications like pirfenidone or nintedanib.
- You qualify for a lung transplant based on declining lung function or other criteria, but you have decided not to have a transplant.
- You have not had any prior cellular immunotherapy (like CAR-T) in the last 3 months.
- Your blood counts are adequate: hematocrit above 30%, lymphocyte count above 0.5 billion/L, and platelet count above 60 billion/L.
- You do not have a history of blood clots, active infections, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cell therapy called REGEND007 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the treatment can help improve walking distance or lung function.
This trial tests a new inhaled treatment made from placental stem cells to see if it's safe and helps slow scarring in the lungs (idiopathic pulmonary fibrosis). The treatment is breathed in through a nebulizer, similar to an asthma inhaler.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial is testing a new stem cell therapy made from menstrual blood (SC01009) for people with IPF. It may help reduce lung scarring and improve breathing. Participants must already be on standard IPF treatment.
This trial tests a new cell therapy called CAR-DC for people with advanced solid tumors that have certain markers on their cells. It aims to see if it is safe and works against cancers like lung, liver, stomach, or colorectal cancer that haven't responded to standard treatments.
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
Hear when a new Idiopathic Pulmonary Fibrosis(IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.